EP3902547
CSF1R-hindrar til notkunar við meðhöndlun á krabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
23.12.2019EP published:
20.9.2023EP application number:
19842712.2
EP translation filed:
6.11.2023Grant published:
15.12.2023EPO information:
European Patent Register
Max expiry date:
22.12.2039Expiry date:
22.12.2026Next due date:
31.12.2026
Title in English:
CSF1R INHIBITORS FOR USE IN TREATING CANCERLanguage of the patent:
English
Timeline
Today
23.12.2019EP application
20.9.2023EP Publication
6.11.2023Translation submitted
15.12.2023Registration published
22.12.2026Expires
Owner
Name:
Deciphera Pharmaceuticals, LLCAddress:
200 Smith Street, Waltham, MA 02451, US
Inventor
Name:
FLYNN, Daniel L.Address:
Lawrence, KS 66047, US
Name:
SMITH, Bryan D.Address:
Waltham, MA 02451, US
Name:
SOTO, Rodrigo, RuizAddress:
Waltham, MA 02451, US
Name:
KUIDA, KeisukeAddress:
Waltham, MA 02451, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862786105 PDate:
28.12.2018Country:
US
Number:
201962926341 PDate:
25.10.2019Country:
US
Number:
201962933830 PDate:
11.11.2019Country:
US
Supplementary protection
SPC number:
SPC548
Classification
Categories:
A61K 31/506, A61K 31/337, A61K 31/357, A61K 31/4184, A61K 31/437, A61K 31/4523, A61K 31/519, A61K 31/7068, A61K 45/06, A61P 35/00, A61P 35/02, A61P 35/04, G01N 33/50
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 4.1.2024
Expires: 22.12.2024
Payer: Árnason Faktor ehf.
Number: 6
Paid: 10.12.2024
Expires: 22.12.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 19.12.2025
Expires: 22.12.2026
Payer: Árnason Faktor ehf.